Similarly, Brunkhorst et al. demonstrated that monoallelic SLC34A1 variant carriers exhibited stage 2 CKD in 50% of cases at the time of initial presentation and in 10.5% of cases at the final follow-up assessment [21]. This evidence concerns the gene SLC34A1 and chronic kidney disease.